This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Cannabis ETFs Soar Double-Digits on Friday: Here's Why
by Sanghamitra Saha
Cannabis ETFs explode on reform buzz. CNBS, WEED, MSOS and MJ jumped double-digits on Dec. 12, 2025 as Trump reportedly weighs reclassifying marijuana, boosting optimism.
The Zacks Analyst Blog Highlights MSOS, CNBS, WEED, MJ and YOLO
by Zacks Equity Research
Zacks Analyst Blog highlights MSOS, CNBS, WEED, MJ, and YOLO as marijuana ETFs soar over 100% in three months on U.S. legalization hopes and investor optimism.
From Loss to Lift-Off: Marijuana ETFs Rebound on Legalization Prospects
by Aparajita Dutta
Marijuana ETFs, such as WEED, MSOS, and CNBS, are rebounding as hopes for rescheduling boost investor optimism.
Top-Performing ETFs of Last Week
by Sanghamitra Saha
ETFs tied to cannabis, Ethereum and Chinese tech stocks topped last week's winners list. Top performers were KSTR, YOLO, ARKZ, CHIQ and CNXT.
Cannabis ETFs Soar as Trump Mulls Over Marijuana Reclassification
by Sweta Killa
Cannabis ETFs like WEED, CNBS and MJ surge after Trump confirmed that his administration is weighing marijuana's move from Schedule I to Schedule III.
Is Rescheduling a Certainty for Cannabis? ETFs That Surge
by Sanghamitra Saha
In a White House meeting, Vice President Kamala Harris this week urged the DEA to expedite the rescheduling of marijuana. President Biden also lately talked about ongoing efforts to review the federal classification of marijuana, hinting at his commitment to potential reforms
Cannabis ETFs Outperform in January
by Sweta Killa
The cannabis industry has been performing well this year after the US Drug Enforcement Administration started reviewing the potential reclassification of cannabis from Schedule I to Schedule III.
Cannabis ETFs Spike on Marijuana Classification Review
by Sweta Killa
Marijuana stocks spiked following the report that the US Drug Enforcement Administration (¿¿¿DEA¿¿¿) is reviewing the potential reclassification of cannabis from Schedule I to Schedule III.
Behind the Recent Surge in Marijuana ETFs
by Sanghamitra Saha
In a significant development, the Department of Health and Human Services (HHS) has recently initiated a review of marijuana's classification under the Controlled Substances Act.
Cannabis Stocks Are Moving Higher
by Brian Bolan
A looking into what is driving the recent spike in cannabis stocks.